In addition, LFA-1 and CR3 have been associated with other autoimmune disorders, such as systemic lupus erythematosus [28,29] and psoriasis, where an anti-LFA-1 antibody (Efalizumab) had been marketed but was withdrawn due to safety concerns. Here, ITGB2 is linked to systemic lupus erythematosus.